Anaptysbio Stock Probability of Future Stock Price Finishing Under 22.0

ANAB Stock  USD 14.55  0.45  3.00%   
AnaptysBio's future price is the expected price of AnaptysBio instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of AnaptysBio performance during a given time horizon utilizing its historical volatility. Check out AnaptysBio Backtesting, AnaptysBio Valuation, AnaptysBio Correlation, AnaptysBio Hype Analysis, AnaptysBio Volatility, AnaptysBio History as well as AnaptysBio Performance.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
  
As of December 22, 2024, Price To Sales Ratio is expected to decline to 31.93. In addition to that, Price Earnings Ratio is expected to decline to -3.7. Please specify AnaptysBio's target price for which you would like AnaptysBio odds to be computed.

AnaptysBio Target Price Odds to finish below 22.0

The tendency of AnaptysBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay under $ 22.00  after 90 days
 14.55 90 days 22.00 
about 26.53
Based on a normal probability distribution, the odds of AnaptysBio to stay under $ 22.00  after 90 days from now is about 26.53 (This AnaptysBio probability density function shows the probability of AnaptysBio Stock to fall within a particular range of prices over 90 days) . Probability of AnaptysBio price to stay between its current price of $ 14.55  and $ 22.00  at the end of the 90-day period is about 21.86 .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.09 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, AnaptysBio will likely underperform. Additionally AnaptysBio has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   AnaptysBio Price Density   
       Price  

Predictive Modules for AnaptysBio

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AnaptysBio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
7.5814.3721.16
Details
Intrinsic
Valuation
LowRealHigh
11.4118.2024.99
Details
Naive
Forecast
LowNextHigh
1.468.2515.04
Details
12 Analysts
Consensus
LowTargetHigh
27.0729.7533.02
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as AnaptysBio. Your research has to be compared to or analyzed against AnaptysBio's peers to derive any actionable benefits. When done correctly, AnaptysBio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in AnaptysBio.

AnaptysBio Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. AnaptysBio is not an exception. The market had few large corrections towards the AnaptysBio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AnaptysBio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AnaptysBio within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.24
β
Beta against Dow Jones3.09
σ
Overall volatility
7.12
Ir
Information ratio -0.18

AnaptysBio Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AnaptysBio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AnaptysBio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
AnaptysBio generated a negative expected return over the last 90 days
AnaptysBio has high historical volatility and very poor performance
The company reported the previous year's revenue of 17.16 M. Net Loss for the year was (163.62 M) with loss before overhead, payroll, taxes, and interest of (78.51 M).
AnaptysBio currently holds about 442.15 M in cash with (120.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 98.0% of the company shares are held by institutions such as insurance companies
Latest headline from thelincolnianonline.com: AnaptysBio Price Target Cut to 36.00 by Analysts at JPMorgan Chase Co.

AnaptysBio Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AnaptysBio Stock often depends not only on the future outlook of the current and potential AnaptysBio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AnaptysBio's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding26.9 M
Cash And Short Term Investments390.9 M

AnaptysBio Technical Analysis

AnaptysBio's future price can be derived by breaking down and analyzing its technical indicators over time. AnaptysBio Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of AnaptysBio. In general, you should focus on analyzing AnaptysBio Stock price patterns and their correlations with different microeconomic environments and drivers.

AnaptysBio Predictive Forecast Models

AnaptysBio's time-series forecasting models is one of many AnaptysBio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary AnaptysBio's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about AnaptysBio

Checking the ongoing alerts about AnaptysBio for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for AnaptysBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
AnaptysBio generated a negative expected return over the last 90 days
AnaptysBio has high historical volatility and very poor performance
The company reported the previous year's revenue of 17.16 M. Net Loss for the year was (163.62 M) with loss before overhead, payroll, taxes, and interest of (78.51 M).
AnaptysBio currently holds about 442.15 M in cash with (120.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 98.0% of the company shares are held by institutions such as insurance companies
Latest headline from thelincolnianonline.com: AnaptysBio Price Target Cut to 36.00 by Analysts at JPMorgan Chase Co.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:
Check out AnaptysBio Backtesting, AnaptysBio Valuation, AnaptysBio Correlation, AnaptysBio Hype Analysis, AnaptysBio Volatility, AnaptysBio History as well as AnaptysBio Performance.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.05)
Revenue Per Share
2.086
Quarterly Revenue Growth
8.047
Return On Assets
(0.18)
Return On Equity
(1.62)
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.